Morgan Stanley analyst Judah Frommer assumed coverage of Blueprint Medicines (BPMC) with an Equal Weight rating and price target of $120, up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback